DK1383733T3 - Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser - Google Patents

Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser

Info

Publication number
DK1383733T3
DK1383733T3 DK02701498T DK02701498T DK1383733T3 DK 1383733 T3 DK1383733 T3 DK 1383733T3 DK 02701498 T DK02701498 T DK 02701498T DK 02701498 T DK02701498 T DK 02701498T DK 1383733 T3 DK1383733 T3 DK 1383733T3
Authority
DK
Denmark
Prior art keywords
aryl
joined
preparation
azapolycyclic compounds
domains
Prior art date
Application number
DK02701498T
Other languages
English (en)
Inventor
Robert Alan Singer
Jason Daniel Mckinley
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1383733T3 publication Critical patent/DK1383733T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
DK02701498T 2001-04-20 2002-03-04 Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser DK1383733T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28513101P 2001-04-20 2001-04-20
PCT/IB2002/000660 WO2002085843A2 (en) 2001-04-20 2002-03-04 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Publications (1)

Publication Number Publication Date
DK1383733T3 true DK1383733T3 (da) 2008-06-09

Family

ID=23092860

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02701498T DK1383733T3 (da) 2001-04-20 2002-03-04 Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser

Country Status (25)

Country Link
US (2) US7091372B2 (da)
EP (1) EP1383733B1 (da)
JP (1) JP2004527545A (da)
KR (1) KR100551183B1 (da)
CN (1) CN1321107C (da)
AR (2) AR035957A1 (da)
AT (1) ATE388135T1 (da)
AU (1) AU2002234836B2 (da)
BR (1) BR0208992A (da)
CA (1) CA2443946A1 (da)
CZ (1) CZ20032814A3 (da)
DE (1) DE60225433T2 (da)
DK (1) DK1383733T3 (da)
ES (1) ES2300430T3 (da)
HK (1) HK1062170A1 (da)
HU (1) HUP0303811A3 (da)
IL (1) IL157881A0 (da)
MX (1) MXPA03009527A (da)
PL (1) PL366657A1 (da)
PT (1) PT1383733E (da)
RU (1) RU2282619C9 (da)
TW (1) TWI244472B (da)
WO (1) WO2002085843A2 (da)
YU (1) YU78303A (da)
ZA (1) ZA200307205B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4315808B2 (ja) * 2001-11-16 2009-08-19 シーディーティー オックスフォード リミテッド 発光装置及びそれに使用される装置
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
US20070066827A1 (en) * 2003-01-15 2007-03-22 Pfizer Inc. Process for the preparation of aryl fused polycyclic lactams
CA2527337A1 (en) * 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
CA2533100A1 (en) * 2003-07-21 2005-01-27 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP1951668B1 (en) * 2005-11-16 2010-04-14 F.Hoffmann-La Roche Ag Novel process for the preparation of thoc
DE102006024903A1 (de) * 2006-05-24 2007-11-29 Basf Ag Verfahren zur Vermeidung von Fumarsäureablagerungen bei der Herstellung von Maleinsäureanhydrid
US8304436B2 (en) * 2007-05-16 2012-11-06 Nycomed Gmbh Pyrazolone derivatives as PDE4 inhibitors
EP2019107A1 (en) 2007-07-26 2009-01-28 Dynamit Nobel GmbH Explosivstoff- und Systemtechnik Use of phosphonium salts in coupling reactions and process for their manufacture
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
KR101603427B1 (ko) * 2014-08-14 2016-03-15 영남대학교 산학협력단 케스케이드 반응을 통한 인덴 유도체의 효율적 합성방법
CN104478803A (zh) * 2014-12-19 2015-04-01 连云港恒运医药科技有限公司 伐尼克兰中间体及其硝基还原杂质的制备方法
WO2017027933A1 (en) * 2015-08-14 2017-02-23 Boulos & Cooper Pharmaceuticals Pty Ltd Synthesis of aryl compounds
CN110023331A (zh) 2016-07-07 2019-07-16 霍华休斯医学研究院 经修饰的配体门控的离子通道及使用方法
CA3082389A1 (en) * 2017-11-10 2019-05-16 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
CN111995519B (zh) * 2020-09-26 2022-08-26 安徽金禾实业股份有限公司 一种3-甲氧基丙烯酸甲酯的制备方法
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479598A (en) * 1992-10-23 1995-12-26 International Business Machines Corporation Compact graphical parallel program user output interface controlled directly by the parallel computer program
DE69409445D1 (de) * 1993-07-27 1998-05-14 Ibm Prozessüberwachung in einem Mehrfachverarbeitungsanbieter
US6289368B1 (en) * 1995-12-27 2001-09-11 First Data Corporation Method and apparatus for indicating the status of one or more computer processes
US5928323A (en) * 1996-05-30 1999-07-27 Sun Microsystems, Inc. Apparatus and method for dynamically generating information with server-side software objects
FR2751448B1 (fr) * 1996-07-17 1999-01-15 Bull Sa Procede de surveillance en temps reel d'un systeme informatique pour son administration et l'aide a sa maintenance en phase d'exploitation
US6112194A (en) * 1997-07-21 2000-08-29 International Business Machines Corporation Method, apparatus and computer program product for data mining having user feedback mechanism for monitoring performance of mining tasks
US6119165A (en) * 1997-11-17 2000-09-12 Trend Micro, Inc. Controlled distribution of application programs in a computer network
US6100887A (en) * 1997-12-05 2000-08-08 At&T Corporation Reusable reversible progress indicator software component for a graphical user interface
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
SI1044189T2 (sl) * 1997-12-31 2015-05-29 Pfizer Products Inc. Z arilom kondenzirane azapoliciklične spojine
US6151357A (en) * 1998-01-16 2000-11-21 Aspect Communications Corporation Method and apparatus for displaying a visual indication of a transmission status
US6108003A (en) * 1998-03-18 2000-08-22 International Business Machines Corporation Maintaining visibility and status indication of docked applications and application bars
ID26700A (id) * 1998-04-29 2001-02-01 Pfizer Prod Inc Senyawa-senyawa azapolisiklik yang bercampur dengan aril
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
AU5667100A (en) * 1999-07-02 2001-01-22 Prescient Neuropharma Inc. Novel aminoindanes
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US20010036949A1 (en) * 2000-05-09 2001-11-01 Coe Jotham Wadsworth Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)

Also Published As

Publication number Publication date
ATE388135T1 (de) 2008-03-15
PL366657A1 (en) 2005-02-07
CA2443946A1 (en) 2002-10-31
EP1383733A2 (en) 2004-01-28
HUP0303811A2 (hu) 2004-03-01
KR100551183B1 (ko) 2006-02-13
EP1383733B1 (en) 2008-03-05
ES2300430T3 (es) 2008-06-16
CN1503781A (zh) 2004-06-09
PT1383733E (pt) 2008-04-15
AU2002234836B2 (en) 2007-08-23
TWI244472B (en) 2005-12-01
MXPA03009527A (es) 2004-02-12
US7186870B2 (en) 2007-03-06
CN1321107C (zh) 2007-06-13
WO2002085843A2 (en) 2002-10-31
AR043636A2 (es) 2005-08-03
AR035957A1 (es) 2004-07-28
US20060079707A1 (en) 2006-04-13
YU78303A (sh) 2006-05-25
HUP0303811A3 (en) 2008-05-28
IL157881A0 (en) 2004-03-28
US7091372B2 (en) 2006-08-15
JP2004527545A (ja) 2004-09-09
US20030060624A1 (en) 2003-03-27
RU2003130751A (ru) 2005-03-27
KR20030092087A (ko) 2003-12-03
DE60225433D1 (de) 2008-04-17
RU2282619C9 (ru) 2006-12-20
RU2282619C2 (ru) 2006-08-27
ZA200307205B (en) 2004-09-15
CZ20032814A3 (cs) 2004-08-18
HK1062170A1 (en) 2004-10-21
WO2002085843A3 (en) 2003-06-05
DE60225433T2 (de) 2008-06-12
BR0208992A (pt) 2004-04-27

Similar Documents

Publication Publication Date Title
DK1383733T3 (da) Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
DK2380568T3 (da) Fremgangsmåde til fremstilling og krystallisation af reduceret coenzyme Q 10
DK1180518T3 (da) 5-pyridyl-1,3-azolforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK1044969T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af anti-cancer forbindelser
NO20003530D0 (no) Vedvarende frigivelsessammensetning, metode for dens produksjon og anvendelse derav
DK1181272T3 (da) Fremgangsmåde til fremstilling af rent citalopram
DK1181713T3 (da) Fremgangsmåde til fremstilling af rent citalopram
NO20004896D0 (no) Pyridazinonhydrokloridforbindelse og fremgangsmÕte for fremstilling derav
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
NO20032332D0 (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
NO20035738D0 (no) Kontrollert frigivelsessammensetning og metode for å produsere det samme
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1279665T3 (da) Fremgangsmåde til fremstilling af perindopril, analoge forbindelser og salte heraf ved anvendelse af 2,5-dioxo-oxazolidin-mellemforbindelser
DK1147075T3 (da) Fremgangsmåde til fremstilling af L-phenylephrinhydrochlorid
DK1328538T3 (da) Fremgangsmåde og mellemprodukter til fremstilling af 7-substituerede antiöstrogener
NO20033433L (no) Fremgangsmåte for fremstilling av 2-(2-pyridylmetyl)sulfinyl- 1H-benzimidasol
DK1138677T3 (da) Fremgangsmåde til fremstilling af 11-amino-3-chlor-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]-thiazepin og anvendelse til syntese af tianeptin
DK1399424T3 (da) Fremgangsmåde til fremstilling af 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepin-5-carboxamid og 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carboxamid
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
NO20013735D0 (no) Fremgangsmåte til fremstilling av di-iso-butaner, di-iso- butener og di-n-butener fra feltbutaner
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DK0965589T3 (da) Fremgangsmåde og mellemprodukter til fremstillingen af pyridin-2,3-dicarboxylatforbindelser
DK1131299T3 (da) Fremgangsmåde til fremstilling af 1-substituerede 5- eller 3-hydroxypyrazoler
NO20031108D0 (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
DK1341758T3 (da) Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme